Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases

被引：0
|
作者：
Siddharth Singh
Herbert C. Heien
Lindsey Sangaralingham
Nilay D. Shah
William J. Sandborn
机构：
[1] University of California San Diego,Division of Gastroenterology, Department of Medicine
[2] University of California San Diego,Division of Biomedical Informatics, Department of Medicine
[3] Mayo Clinic,Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
[4] Mayo Clinic,Division of Health Care Policy and Research, Department of Health Services Research
来源：
Digestive Diseases and Sciences | 2022年 / 67卷
关键词：
Cancer; Safety; Choice; Colitis; Biologics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2510 / 2516
页数：6
相关论文
共 50 条
  • [31] Infectious complications of tumor necrosis factor-α antagonists
    Bakleh, M
    Tleyjeh, I
    Matteson, EL
    Osmon, DR
    Berbari, EF
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2005, 44 (06) : 443 - 448
  • [32] Clinical Features of Active Tuberculosis Developed During Anti-Tumor Necrosis Factor-α Therapy in Patients With Inflammatory Bowel Diseases
    Choi, Chang Hwan
    Lee, Jang Wook
    GASTROENTEROLOGY, 2015, 148 (04) : S231 - S231
  • [33] Infections associated with tumor necrosis factor-α antagonists
    Rychly, DJ
    DiPiro, JT
    PHARMACOTHERAPY, 2005, 25 (09): : 1181 - 1192
  • [34] RISK OF INFECTIONS WITH USTEKINUMAB AND TOFACITINIB COMPARED TO TUMOR NECROSIS FACTOR ANTANOGISTS IN INFLAMMATORY BOWEL DISEASES
    Cheng, David
    Kochar, Bharati
    Cai, Tianxi
    Ananthakrishnan, Ashwin
    GASTROENTEROLOGY, 2022, 162 (07) : S813 - S814
  • [35] Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update
    Leso, Veruscka
    Leggio, Lorenzo
    Armuzzi, Alessandro
    Gasbarrini, Giovanni
    Gasbarrini, Antonio
    Addolorato, Giovanni
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (07) : 779 - 786
  • [36] Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease
    Ordas, Ingrid
    Feagan, Brian G.
    Sandborn, William J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (10) : 1079 - 1087
  • [37] TUMOR NECROSIS FACTOR IMPACTS INFLIXIMAB CLEARANCE IN INFLAMMATORY BOWEL DISEASES
    Young, Leslie
    Dervieux, Thierry
    Panetta, John C.
    Mould, Diane R.
    Eser, Alexander
    Reinisch, Walter
    GASTROENTEROLOGY, 2021, 160 (06) : S706 - S706
  • [38] Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
    Lemaitre, Magali
    Kirchgesner, Julien
    Rudnichi, Annie
    Carrat, Fabrice
    Zureik, Mahmoud
    Carbonnel, Franck
    Dray-Spira, Rosemary
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (17): : 1679 - 1686
  • [39] No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis
    Yzet, Clara
    Diouf, Momar
    Singh, Siddarth
    Brazier, Franck
    Turpin, Justine
    Nguyen-Khac, Eric
    Meynier, Jonathan
    Fumery, Mathurin
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (04) : 668 - +
  • [40] Risk of Demyelinating Diseases in the Central Nervous System in Patients With Inflammatory Bowel Disease Treated With Tumor Necrosis Factor Inhibitors
    Andersen, Nynne Nyboe
    Pasternak, Bjorn
    Andersson, Mikael
    Nielsen, Nete Munk
    Jess, Tine
    JAMA INTERNAL MEDICINE, 2015, 175 (12) : 1990 - +
12345